TIAA CREF Investment Management LLC reduced its position in shares of Ignyta Inc (NASDAQ:RXDX) by 30.6% in the 4th quarter, Holdings Channel reports. The firm owned 288,377 shares of the biopharmaceutical company’s stock after selling 127,209 shares during the quarter. TIAA CREF Investment Management LLC’s holdings in Ignyta were worth $7,700,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in RXDX. Eagle Asset Management Inc. acquired a new stake in Ignyta during the fourth quarter worth about $60,248,000. Gardner Lewis Asset Management L P acquired a new stake in Ignyta during the fourth quarter worth about $49,431,000. Alliancebernstein L.P. increased its position in Ignyta by 1,414.3% during the fourth quarter. Alliancebernstein L.P. now owns 1,746,002 shares of the biopharmaceutical company’s stock worth $46,618,000 after purchasing an additional 1,630,702 shares during the last quarter. Carillon Tower Advisers Inc. acquired a new stake in Ignyta during the fourth quarter worth about $41,780,000. Finally, Alpine Associates Management Inc. acquired a new stake in Ignyta during the fourth quarter worth about $41,028,000. Hedge funds and other institutional investors own 72.28% of the company’s stock.
Shares of RXDX stock opened at $26.98 on Thursday. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.34. Ignyta Inc has a 1-year low of $5.80 and a 1-year high of $27.10.
ILLEGAL ACTIVITY NOTICE: “Ignyta Inc (RXDX) Position Cut by TIAA CREF Investment Management LLC” was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://dakotafinancialnews.com/2018/04/12/ignyta-inc-rxdx-position-cut-by-tiaa-cref-investment-management-llc.html.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Want to see what other hedge funds are holding RXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ignyta Inc (NASDAQ:RXDX).
Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.